Advanced search
Publication Cover
Expert Opinion on Medical Diagnostics Volume 1, 2007 - Issue 1
Journal homepage
17
Views
0
CrossRef citations to date
0
Altmetric
Review

Advances in molecular diagnostics of myeloproliferative disorders

Brijesh Arora Associate Professor, Tata Memorial Hospital, Division of Medical Oncology, Mumbai, India
, MD DM &
Ayalew Tefferi Professor of Hematology and Medicine, Mayo Clinic College of Medicine, Division of Hematology, 200 First Street SW, Rochester, MN 55905, Minnesota, USA +1 507 284 3159; +1 507 266 4972; [email protected]
, MD
Pages 65-80 | Published online: 12 Sep 2007

Bibliography

  • BENNETT JM, CATOVSKY D, DANIEL MT et al.: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br. J. Haematol. (1994) 87(4):746-754.
  • DAMESHEK W: Some speculations on the myeloproliferative syndromes. Blood (1951) 6(4):372-375.
  • VARDIMAN JW, HARRIS NL, BRUNNING RD: The World Health Organization (WHO) classification of the myeloid neoplasms. Blood (2002) 100(7):2292-2302.
  • FIALKOW PJ, GARTLER SM, YOSHIDA A: Clonal origin of chronic myelocytic leukemia in man. Proc. Natl. Acad. Sci. USA (1967) 58(4):1468-1471.
  • ADAMSON JW, FIALKOW PJ, MURPHY S, PRCHAL JF, STEINMANN L: Polycythemia vera: stem-cell and probable clonal origin of the disease. N. Engl. J. Med. (1976) 295(17):913-916.
  • JACOBSON RJ, SALO A, FIALKOW PJ: Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood (1978) 51(2):189-194.
  • FIALKOW PJ, FAGUET GB, JACOBSON RJ, VAIDYA K, MURPHY S: Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood (1981) 58(5):916-919.
  • NOWELL PC, HUNGERFORD DA: Chromosome studies on normal and leukemic human leukocytes. J. Natl. Cancer Inst. (1960) 25:85-109.
  • DE KLEIN A, VAN KESSEL AG, GROSVELD G et al.: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1982) 300(5894):765-767.
  • KONOPKA JB, WATANABE SM, WITTE ON: An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell (1984) 37(3):1035-1042.
  • DALEY GQ, VAN ETTEN RA, BALTIMORE D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 247(4944):824-830.
  • LUGO TG, PENDERGAST AM, MULLER AJ, WITTE ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science (1990) 247(4946):1079-1082.
  • VONCKEN JW, KAARTINEN V, PATTENGALE PK et al.: BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Blood (1995) 86(12):4603-4611.
  • COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348(13):1201-1214.
  • PARDANANI A, BROCKMAN SR, PATERNOSTER SF et al.: FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood (2004) 104(10):3038-3045.
  • PARDANANI A, REEDER TL, KIMLINGER TK et al.: Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease. Leuk. Res. (2003) 27(8):739-742.
  • LONGLEY BJ, REGUERA MJ, MA Y: Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res. (2001) 25(7):571-576.
  • GOLUB TR, BARKER GF, LOVETT M, GILLILAND DG: Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 77(2):307-316.
  • WILKINSON K, VELLOSO ER, LOPES LF et al.: Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood (2003) 102(12):4187-4190.
  • STEER EJ, CROSS NC: Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor β. Acta Haematol. (2002) 107(2):113-122.
  • BAXTER EJ, KULKARNI S, VIZMANOS JL et al.: Novel translocations that disrupt the platelet-derived growth factor receptor β (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br. J. Haematol. (2003) 120(2):251-256.
  • APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. (2002) 347(7):481-487.
  • SOHAL J, CHASE A, MOULD S et al.: Identification of four new translocations involving FGFR1 in myeloid disorders. Genes Chromosomes Cancer (2001) 32(2):155-163.
  • XIAO S, NALABOLU SR, ASTER JC et al.: FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. (1998) 18(1):84-87.
  • KULKARNI S, REITER A, SMEDLEY D, GOLDMAN JM, CROSS NC: The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome. Genomics (1999) 55(1):118-121.
  • AGUIAR RC, MACDONALD D, MASON PJ, CROSS NC, GOLDMAN JM: Myeloproliferative disorder associated with 8p11 translocations. Blood (1995) 86(2):834-835.
  • TEFFERI A, GILLILAND DG: Oncogenes in myeloproliferative disorders. Cell Cycle (2007) 6(5):550-566.
  • TARTAGLIA M, NIEMEYER CM, FRAGALE A et al.: Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. (2003) 34(2):148-150.
  • LOH ML, VATTIKUTI S, SCHUBBERT S et al.: Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2004) 103(6):2325-2331.
  • SIDE LE, EMANUEL PD, TAYLOR B et al.: Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood (1998) 92(1):267-272.
  • BENCH AJ, PAHL HL: Chromosomal abnormalities and molecular markers in myeloproliferative disorders. Semin. Hematol. (2005) 42(4):196-205.
  • JAMES C, UGO V, LE COUEDIC JP et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 434(7037):1144-1148.
  • LEVINE RL, WADLEIGH M, COOLS J et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 7(4):387-397.
  • KRALOVICS R, PASSAMONTI F, BUSER AS et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. (2005) 352(17):1779-1790.
  • BAXTER EJ, SCOTT LM, CAMPBELL PJ et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 365(9464):1054-1061.
  • ZHAO R, XING S, LI Z et al.: Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. (2005) 280(24):22788-22792.
  • STEENSMA DP, DEWALD GW, LASHO TL et al.: The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 106(4):1207-1209.
  • JONES AV, KREIL S, ZOI K et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood (2005) 106(6):2162-2168.
  • TEFFERI A, GILLILAND G: Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system. Best Pract. Res. Clin. Haematol. (2006) 19(3):365-385.
  • KURZROCK R, GUTTERMAN JU, TALPAZ M: The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (1988) 319(15):990-998.
  • MORGAN GJ, WIEDEMANN LM: Molecular biology of the Philadelphia positive leukaemias. Recenti. Prog. Med. (1989) 80(10):508-519.
  • MELO JV: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood (1996) 88(7):2375-2384.
  • SHEPHERD P, SUFFOLK R, HALSEY J, ALLAN N: Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of IFN in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br. J. Haematol. (1995) 89(3):546-554.
  • HURET JL: Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia. Hum. Genet. (1990) 85(6):565-568.
  • SAKURAI M, SANDBERG AA: The chromosomes and causation of human cancer and leukemia. XVIII. The missing Y in acute myeloblastic leukemia (AML) and Ph1-positive chronic myelocytic leukemia (CML). Cancer (1976) 38(2):762-769.
  • HEIM S, BILLSTROM R, KRISTOFFERSSON U et al.: Variant Ph translocations in chronic myeloid leukemia. Cancer Genet. Cytogenet. (1985) 18(3):215-227.
  • ENGEL E, MCGEE BJ, FLEXNER JM, RUSSELL MT, MYERS BJ: Letter: Philadelphia chromosome (Ph1) translocation in an apparently Ph1 negative, minus G22, case of chronic myeloid leukemia. N. Engl. J. Med. (1974) 291(3):154.
  • EPNER DE, KOEFFLER HP: Molecular genetic advances in chronic myelogenous leukemia. Ann. Intern. Med. (1990) 113(1):3-6.
  • MORRIS CM, HEISTERKAMP N, KENNEDY MA, FITZGERALD PH, GROFFEN J: Ph-negative chronic myeloid leukemia: molecular analysis of ABL insertion into M-BCR on chromosome 22. Blood (1990) 76(9):1812-1818.
  • DEWALD GW, SCHAD CR, CHRISTENSEN ER et al.: The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL. Cancer Genet. Cytogenet. (1993) 71(1):7-14.
  • YANAGI M, SHINJO K, TAKESHITA A et al.: Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells. Leukemia (1999) 13(4):542-552.
  • SCHOCH C, SCHNITTGER S, BURSCH S et al.: Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia (2002) 16(1):53-59.
  • COX MC, MAFFEI L, BUFFOLINO S et al.: A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias. Am. J. Clin. Pathol. (1998) 109(1):24-31.
  • MELO JV, YAN XH, DIAMOND J et al.: Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results. Leukemia (1996) 10(7):1217-1221.
  • WELLS SJ, PHILLIPS CN, WINTON EF, FARHI DC: Reverse transcriptase-polymerase chain reaction for bcr/abl fusion in chronic myelogenous leukemia. Am. J. Clin. Pathol. (1996) 105(6):756-760.
  • FRENOY N, CHABLI A, SOL O et al.: Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts. Leukemia (1994) 8(8):1411-1414.
  • MORGAN GJ, HUGHES T, JANSSEN JW et al.: Polymerase chain reaction for detection of residual leukaemia. Lancet (1989) 1(8644):928-929.
  • HUGHES TP, MORGAN GJ, MARTIAT P, GOLDMAN JM: Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood (1991) 77(4):874-878.
  • CROSS NC, FENG L, CHASE A et al.: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood (1993) 82(6):1929-1936.
  • LIN F, VAN RHEE F, GOLDMAN JM, CROSS NC: Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood (1996) 87(10):4473-4478.
  • THOMPSON JD, BRODSKY I, YUNIS JJ: Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood (1992) 79(6):1629-1635.
  • NAGEL S, SCHMIDT M, THIEDE C, HUHN D, NEUBAUER A: Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR). Nucleic Acids Res. (1996) 24(20):4102-4103.
  • HOCHHAUS A, LIN F, REITER A et al.: Quantification of residual disease in chronic myelogenous leukemia patients on IFN-α therapy by competitive polymerase chain reaction. Blood (1996) 87(4):1549-1555.
  • FREEMAN WM, WALKER SJ, VRANA KE: Quantitative RT-PCR: pitfalls and potential. Biotechniques (1999) 26(1):112-122, 124-125.
  • EMIG M, SAUSSELE S, WITTOR H et al.: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia (1999) 13(11):1825-1832.
  • KANTARJIAN HM, TALPAZ M, CORTES J et al.: Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin. Cancer Res. (2003) 9(1):160-166.
  • STENTOFT J, PALLISGAARD N, KJELDSEN E et al.: Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction. Eur. J. Haematol. (2001) 67(5-6):302-308.
  • LANGE T, BUMM T, OTTO S et al.: Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica (2004) 89(1):49-57.
  • GABERT J, BEILLARD E, VAN DER VELDEN VH et al.: Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe against cancer program. Leukemia (2003) 17(12):2318-2357.
  • BEILLARD E, PALLISGAARD N, VAN DER VELDEN VH et al.: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia (2003) 17(12):2474-2486.
  • VAN DER VELDEN VH, HOCHHAUS A, CAZZANIGA G et al.: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia (2003) 17(6):1013-1034.
  • HUGHES T, BRANFORD S: Molecular monitoring of chronic myeloid leukemia. Semin. Hematol. (2003) 40(2 Suppl. 2):62-68.
  • HUGHES T, DEININGER M, HOCHHAUS A et al.: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood (2006) 108(1):28-37.
  • SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2(2):117-125.
  • BRANFORD S, RUDZKI Z, WALSH S et al.: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood (2002) 99(9):3472-3475.
  • BRANFORD S, RUDZKI Z, WALSH S et al.: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood (2003) 102(1):276-283.
  • GAMBACORTI-PASSERINI CB, GUNBY RH, PIAZZA R et al.: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. (2003) 4(2):75-85.
  • ROCHE-LESTIENNE C, SOENEN-CORNU V, GRARDEL-DUFLOS N et al.: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood (2002) 100(3):1014-1018.
  • SOVERINI S, COLAROSSI S, GNANI A et al.: Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica (2007) 92(3):401-404.
  • SOVERINI S, MARTINELLI G, ROSTI G et al.: ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J. Clin. Oncol. (2005) 23(18):4100-4109.
  • SOVERINI S, COLAROSSI S, GNANI A et al.: Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin. Cancer Res. (2006) 12(24):7374-7379.
  • HUGHES T: ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematol. Am. Soc. Hematol. Educ. Program (2006):211-218.
  • IRVING JA, O'BRIEN S, LENNARD AL et al.: Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to imatinib. Clin. Chem. (2004) 50(7):1233-1237.
  • SOVERINI S, MARTINELLI G, AMABILE M et al.: Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin. Chem. (2004) 50(7):1205-1213.
  • KHORASHAD JS, ANAND M, MARIN D et al.: The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 20(4):658-663.
  • SOREL N, CHAZELAS F, BRIZARD A, CHOMEL JC: Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients. Clin. Chem. (2005) 51(7):1263-1266.
  • KREUZER KA, LE COUTRE P, LANDT O et al.: Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann. Hematol. (2003) 82(5):284-289.
  • WILLIS SG, LANGE T, DEMEHRI S et al.: High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood (2005) 106(6):2128-2137.
  • WHITE D, SAUNDERS V, LYONS AB et al.: In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood (2005) 106(7):2520-2526.
  • WHITE DL, SAUNDERS VA, DANG P et al.: OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood (2006) 108(2):697-704.
  • ZHENG C, LI L, HAAK M et al.: Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia (2006) 20(6):1028-1034.
  • MCLEAN LA, GATHMANN I, CAPDEVILLE R, POLYMEROPOULOS MH, DRESSMAN M: Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin. Cancer Res. (2004) 10(1 Part 1):155-165.
  • RADICH JP, DAI H, MAO M et al.: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA (2006) 103(8):2794-2799.
  • CROSSMAN LC, MORI M, HSIEH YC et al.: In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica (2005) 90(4):459-464.
  • RANE SG, REDDY EP: JAKs, STATs and Src kinases in hematopoiesis. Oncogene (2002) 21(21):3334-3358.
  • RANE SG, REDDY EP: Janus kinases: components of multiple signaling pathways. Oncogene (2000) 19(49):5662-5679.
  • PARGANAS E, WANG D, STRAVOPODIS D et al.: Jak2 is essential for signaling through a variety of cytokine receptors. Cell (1998) 93(3):385-395.
  • SCOTT LM, SCOTT MA, CAMPBELL PJ, GREEN AR: Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood (2006) 108(7):2435-2437.
  • SCOTT LM, TONG W, LEVINE RL et al.: JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. (2007) 356(5):459-468.
  • PARDANANI AD, LEVINE RL, LASHO T et al.: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 108(10):3472-3476.
  • TEFFERI A: Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era. Hematol. Am. Soc. Hematol. Educ. Program (2006) :240-245.
  • TEFFERI A: JAK2 mutations in polycythemia vera – molecular mechanisms and clinical applications. N. Engl. J. Med. (2007) 356(5):444-445.
  • TEFFERI A, GILLILAND DG: The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin. Proc. (2005) 80(7):947-958.
  • JONES AV, SILVER RT, WAGHORN K et al.: Minimal molecular response in polycythemia vera patients treated with imatinib or interferon a. Blood (2006) 107(8):3339-3341.
  • KILADJIAN JJ, CASSINAT B, TURLURE P et al.: High molecular response rate of polycythemia vera patients treated with pegylated IFN-α-2a. Blood (2006) 108(6):2037-2040.
  • LEVINE RL, BELISLE C, WADLEIGH M et al.: X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood (2006) 107(10):4139-4141.
  • CAMPBELL PJ, GRIESSHAMMER M, DOHNER K et al.: V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood (2006) 107(5):2098-2100.
  • MESA RA, POWELL H, LASHO T et al.: JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia. Leuk. Res. (2006) 30(11):1457-1460.
  • WOLANSKYJ AP, LASHO TL, SCHWAGER SM et al.: JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br. J. Haematol. (2005) 131(2):208-213.
  • CAMPBELL PJ, SCOTT LM, BUCK G et al.: Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 366(9501):1945-1953.
  • TEFFERI A, LASHO TL, SCHWAGER SM et al.: The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br. J. Haematol. (2005) 131(3):320-328.
  • HELLER PG, LEV PR, SALIM JP et al.: JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur. J. Haematol. (2006) 77(3):210-216.
  • CHEUNG B, RADIA D, PANTELIDIS P, YADEGARFAR G, HARRISON C: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br. J. Haematol. (2006) 132(2):244-245.
  • SPELETAS M, KATODRITOU E, DAIOU C et al.: Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk. Res. (2007) 31(8):1053-1062.
  • ANTONIOLI E, GUGLIELMELLI P, PANCRAZZI A et al.: Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia (2005) 19(10):1847-1849.
  • PEMMARAJU N, MOLITERNO AR, WILLIAMS D, ROGERS O, SPIVAK JL: Heterogeneous JAK2V617F allele burden in essential thrombocytosis: gender and clinical correlates. ASH Ann. Meeting. Abstr. (2006) 108(11):2679.
  • VANNUCCHI AM, ANTONIOLI E, GUGLIELMELLI P et al.: Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood (2007) 110(3):840-846.
  • VANNUCCHI AM, ANTONIOLIM E, GUGLIELMELLI P et al.: Influence of the Jak2V617F mutational load at diagnosis on major clinical aspects in patients with polycythemia vera. ASH Ann. Meeting Abstr. (2006) 108(11):5.
  • KILADJIAN JJ, CASADEVALL N, VAINCHENKER W, FENAUX P: The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. Pathol. Biol. (Paris) (2007) 55(2):85-87.
  • TEFFERI A, STRAND JJ, LASHO TL et al.: Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy. Cancer (2006) 106(8):1739-1743.
  • VANNUCCHI AM, PANCRAZZI A, BOGANI C, ANTONIOLI E, GUGLIELMELLI P: A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia (2006) 20(6):1055-1060.
  • MCCLURE R, MAI M, LASHO T: Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia (2006) 20(1):168-171.
  • KILADJIAN J-J, CASSINAT B, TURLURE P et al.: Peg IFN{α}-2a in polycythemia vera (PV). Results of a Phase II study by the French “PV-NORD” group. ASH Ann. Meeting Abstr. (2006) 108(11):670.
  • MARKOVA J, PRUKOVA D, VOLKOVA Z, SCHWARZ J: A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation. Leuk. Lymphoma (2007) 48(3):636-639.
  • OLSEN RJ, TANG Z, FARKAS DH et al.: Detection of the JAK2(V617F) mutation in myeloproliferative disorders by melting curve analysis using the LightCycler system. Arch. Pathol. Lab. Med. (2006) 130(7):997-1003.
  • JAMES C, DELHOMMEAU F, MARZAC C et al.: Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia (2006) 20(2):350-353.
  • TEFFERI A, MESA RA, SCHROEDER G et al.: Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br. J. Haematol. (2001) 113(3):763-771.
  • REILLY JT: Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia. Semin. Oncol. (2005) 32(4):359-364.
  • DIEZ-MARTIN JL, GRAHAM DL, PETITT RM, DEWALD GW: Chromosome studies in 104 patients with polycythemia vera. Mayo Clin. Proc. (1991) 66(3):287-299.
  • SESSAREGO M, DEFFERRARI R, DEJANA AM et al.: Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet. Cytogenet. (1989) 43(1):57-65.
  • STEENSMA DP, TEFFERI A: Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol. (2002) 108(2):55-65.
  • BACHER U, HAFERLACH T, KERN W et al.: Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann. Hematol. (2005) 84(4):250-257.
  • DINGLI D, GRAND FH, MAHAFFEY V et al.: Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia. Br. J. Haematol. (2005) 130(2):229-232.
  • TEFFERI A, DINGLI D, LI CY, DEWALD GW: Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia. Cancer (2005) 104(8):1656-1660.
  • DINGLI D, SCHWAGER SM, MESA RA et al.: Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer (2006) 106(9):1985-1989.
  • MESA RA, LI CY, KETTERLING RP et al.: Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood (2005) 105(3):973-977.
  • CHEN Z, SANDBERG AA: Molecular cytogenetic aspects of hematological malignancies: clinical implications. Am. J. Med. Genet. (2002) 115(3):130-141.
  • ZAMORA L, ESPINET B, FLORENSA L et al.: Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients? Cancer Genet. Cytogenet. (2004) 151(2):139-145.
  • NAJFELD V, MONTELLA L, SCALISE A, FRUCHTMAN S: Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br. J. Haematol. (2002) 119(2):558-566.
  • TEMERINAC S, KLIPPEL S, STRUNCK E et al.: Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood (2000) 95(8):2569-2576.
  • TEOFILI L, MARTINI M, LUONGO M et al.: Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. J. Clin. Oncol. (2002) 20(20):4249-4254.
  • MARTINI M, TEOFILI L, LAROCCA LM: Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia. Methods Mol. Med. (2006) 125:265-273.
  • GRIESSHAMMER M, KLIPPEL S, STRUNCK E et al.: PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann. Hematol. (2004) 83(6):364-370.
  • KRALOVICS R, BUSER AS, TEO SS et al.: Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood (2003) 102(5):1869-1871.
  • KLIPPEL S, STRUNCK E, TEMERINAC S et al.: Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood (2003) 102(10):3569-3574.
  • TEFFERI A, LASHO TL, WOLANSKYJ AP, MESA RA: Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood (2004) 103(9):3547-3548.
  • PASSAMONTI F, PIETRA D, MALABARBA L et al.: Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. Br. J. Haematol. (2004) 126(5):650-656.
  • MASTERS GS, BAINES P, JACOBS A: Erythroid colony growth from peripheral blood and bone marrow in polycythaemia. J. Clin. Pathol. (1990) 43(11):937-941.
  • WEINBERG RS: In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin. Hematol. (1997) 34(1):64-69.
  • FLORENSA L, BESSES C, WOESSNER S et al.: Endogenous megakaryocyte and erythroid colony formation from blood in essential thrombocythaemia. Leukemia (1995) 9(2):271-273.
  • REID CD, FIDLER J, KIRK A: Endogenous erythroid clones (EEC) in polycythaemia and their relationship to diagnosis and the response to treatment. Br. J. Haematol. (1988) 68(4):395-400.
  • REID CD: The significance of endogenous erythroid colonies (EEC) in haematological disorders. Blood Rev. (1987) 1(2):133-140.
  • DOBO I, DONNARD M, GIRODON F et al.: Standardization and comparison of endogenous erythroid colony assays performed with bone marrow or blood progenitors for the diagnosis of polycythemia vera. Hematol. J. (2004) 5(2):161-167.
  • DOBO I, MOSSUZ P, CAMPOS L et al.: Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. Hematol. J. (2001) 2(6):396-403.
  • HORIKAWA Y, MATSUMURA I, HASHIMOTO K et al.: Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood (1997) 90(10):4031-4038.
  • MOLITERNO AR, HANKINS WD, SPIVAK JL: Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N. Engl. J. Med. (1998) 338(9):572-580.
  • YOON SY, LI CY, TEFFERI A: Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur. J. Haematol. (2000) 65(3):170-174.
  • LE BLANC K, ANDERSSON P, SAMUELSSON J: Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera. Br. J. Haematol. (2000) 108(1):80-85.
  • DUENSING S, DUENSING A, MERAN JG et al.: Molecular detection of c-mpl thrombopoietin receptor gene expression in chronic myeloproliferative disorders. Mol. Pathol. (1999) 52(3):146-150.
  • TEFFERI A, YOON SY, LI CY: Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood (2000) 96(2):771-772.
  • KLIPPEL S, PAHL HL: Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders. Pathol. Biol. (Paris) (2004) 52(5):267-274.
  • TRANZER JP, DA PRADA M, PLETSCHER A: Storage of 5-hydroxytryptamine in megakaryocytes. J. Cell Biol. (1972) 52(1):191-197.
  • CHAUVEAU J, FERT V, MOREL AM, DELAAGE MA: Rapid and specific enzyme immunoassay of serotonin. Clin. Chem. (1991) 37(7):1178-1184.
  • MAURER-SPUREJ E, DYKER K, GAHL WA, DEVINE DV: A novel immunocytochemical assay for the detection of serotonin in platelets. Br. J. Haematol. (2002) 116(3):604-611.
  • KOCH CA, LASHO TL, TEFFERI A: Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay. Br. J. Haematol. (2004) 127(1):34-39.
  • TEFFERI A, ELLIOTT MA, PARDANANI A: Atypical myeloproliferative disorders: diagnosis and management. Mayo Clin. Proc. (2006) 81(4):553-563.
  • COOLS J, STOVER EH, GILLILAND DG: Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia. Methods Mol. Med. (2006) 125:177-187.
  • TREMPAT P, VILLALVA C, LAURENT G et al.: Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor α receptor: a new clinical target for STI571/Glivec. Oncogene (2003) 22(36):5702-5706.
  • SAFLEY AM, SEBASTIAN S, COLLINS TS et al.: Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-α genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer (2004) 40(1):44-50.
  • PARDANANI A, KETTERLING RP, BROCKMAN SR et al.: CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood (2003) 102(9):3093-3096.
  • VANDENBERGHE P, WLODARSKA I, MICHAUX L et al.: Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia (2004) 18(4):734-742.
  • GRANJO E, LIMA M, LOPES JM et al.: Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report. Acta Haematol. (2002) 107(2):108-112.
  • GUPTA R, KNIGHT CL, BAIN BJ: Receptor tyrosine kinase mutations in myeloid neoplasms. Br. J. Haematol. (2002) 117(3):489-508.
  • GREIPP PT, DEWALD GW, TEFFERI A: Prevalence, breakpoint distribution, and clinical correlates of t(5;12). Cancer Genet. Cytogenet. (2004) 153(2):170-172.
  • MAGNUSSON MK, MEADE KE, NAKAMURA R, BARRETT J, DUNBAR CE: Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor β receptor fusion oncogene. Blood (2002) 100(3):1088-1091.
  • MACDONALD D, REITER A, CROSS NC: The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol. (2002) 107(2):101-107.
  • WALZ C, CHASE A, SCHOCH C et al.: The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia (2005) 19(6):1005-1009.
  • AKIN C, FUMO G, YAVUZ AS et al.: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood (2004) 103(8):3222-3225.
  • TAN A, WESTERMAN D, MCARTHUR GA et al.: Sensitive detection of KIT D816V in patients with mastocytosis. Clin. Chem. (2006) 52(12):2250-2257.
  • TEFFERI A, PARDANANI A: Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr. Opin. Hematol. (2004) 11(1):58-64.
  • MA Y, ZENG S, METCALFE DD et al.: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood (2002) 99(5):1741-1744.
  • FROST MJ, FERRAO PT, HUGHES TP, ASHMAN LK: Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Ther. (2002) 1(12):1115-1124.
  • ZERMATI Y, DE SEPULVEDA P, FEGER F et al.: Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene (2003) 22(5):660-664.
  • PARDANANI A, ELLIOTT M, REEDER T et al.: Imatinib for systemic mast-cell disease. Lancet (2003) 362(9383):535-536.
  • GARCIA-MONTERO AC, JARA-ACEVEDO M, TEODOSIO C et al.: KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood (2006) 108(7):2366-2372.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.